Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9UHF0
UPID:
TKNK_HUMAN
Alternative names:
ZNEUROK1
Alternative UPACC:
Q9UHF0; Q6IAG2; Q71BC6; Q71BC9
Background:
Tachykinin-3, also known as ZNEUROK1, plays a pivotal role in the nervous system. It is a potent vasodilator, secretagogue, and can influence smooth muscle behavior. Its primary function is as a central regulator of gonadal function, highlighting its importance in reproductive biology.
Therapeutic significance:
The protein is linked to Hypogonadotropic hypogonadism 10 with or without anosmia, a condition marked by low sexual development and gonadotropin levels. Understanding Tachykinin-3's role could lead to novel treatments for reproductive disorders.